Silo pharma partners with amplifybio to advance spc-15 for ptsd and anxiety

Amplify bio to complete glp study of spc-15 novel intranasal therapeutic silo study advances spc-15 towards first-in-human trial sarasota, fl, june 26, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has awarded a contract to its contract research organization (cro) partner amplifybio for an investigational new drug (ind)-enabling large animal glp (good laboratory practice) study of its lead asset, spc-15, an intranasal prophylactic treatment for post-traumatic stress disorder (ptsd). the 4-week glp study will evaluate a 28-day repeat intranasal dosing with a 14-day recovery.
SILO Ratings Summary
SILO Quant Ranking